查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球癌症疫苗市场：按类型、技术、给药途径、适应症、最终用户、地区分类 - 预测至 2032 年
市场调查报告书
商品编码
1623615

全球癌症疫苗市场：按类型、技术、给药途径、适应症、最终用户、地区分类 - 预测至 2032 年

Cancer Vaccines Market by Type (Preventive, Therapeutic (Neoantigen)), Technology (Cell-based Vaccine, Recombinant), Indication (Cervical, Prostate), ROA (Intramuscular, Intravenous), End User (Hospitals, Speciality Clinics) - Global Forecast to 2032
出版日期: | 出版商: MarketsandMarkets | 英文 263 Pages | 订单完成后即时交付

价格

全球癌症疫苗市场规模预计将从2024年的106.1亿美元增加至2032年的204.7亿美元以上，复合年增长率为8.6%。

在癌症发病率上升和 mRNA 平台等免疫疗法技术进步的推动下，该市场正在经历强劲增长。Gardasil(HPV) 等预防性疫苗和新抗原疫苗等治疗性候选疫苗正在推动市场创新。强大的研发投资，尤其是在北美和欧洲，加上对个人化治疗的需求不断增长，正在进一步加速采用。

调查范围
调查年份 2022-2032
基准年 2023年
预测期 2024-2032
考虑单位 金额（美元）
按细分市场 按类型、技术、给药途径、适应症、最终用户、地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东/非洲

癌症疫苗市场按类型进一步细分为预防性疫苗和治疗性疫苗（新抗原癌症疫苗和其他癌症疫苗）。由于疾病预防意识不断提高、政府免疫计划以及疫苗开发技术进步，预防性癌症疫苗产业预计将引领癌症疫苗市场。 mRNA 平台等新兴技术可能会推动该行业的成长，因为它们有可能进一步提高疫苗功效并且易于获取。

癌症疫苗市场的给药途径分为静脉注射、肌肉注射和其他给药途径。由于既定的实践、疫苗给药的高效性以及有效免疫反应的产生，肌肉注射 (IM) 给药预计将引领癌症疫苗市场。肌肉注射最适合预防性和治疗性癌症疫苗，因为它具有高疫苗吸收效率并且与任何製剂相容。它也易于在临床和门诊环境中使用，并且只需要对医疗保健提供者进行最少的培训，从而提高了大规模免疫计划的可及性和扩充性。因此，所有这些参数都将 IM 途径定位为癌症疫苗领域的主要且可行的选择。

“北美：癌症疫苗市场份额最大”

从区域来看，市场分为北美、欧洲、亚太地区、拉丁美洲以及中东和非洲。预计北美将在 2023 年主导癌症疫苗市场，并在市场估计和预测期内保持其主导地位。先进的医疗基础设施、对生物技术的高水准投资以及推动该领域创新的主要製药公司的强大影响力是加速市场成长的突出因素。

该报告研究了全球癌症疫苗市场，包括按类型、技术、给药途径、适应症、最终用户、地区和进入市场的公司概况分類的趋势。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章市场概况

  • 介绍
  • 市场动态
  • 影响客户业务的趋势/干扰
  • 价值链分析
  • 生态系分析
  • 技术分析
  • 专利分析
  • 价格分析
  • 2024-2025年重大会议和活动
  • 监管状况
  • 投资金筹措场景
  • 波特五力分析
  • 主要相关人员和采购标准
  • 贸易分析
  • 人工智慧/产生人工智慧对癌症疫苗市场的影响
  • 管道分析

第六章癌症疫苗市场（按类型）

  • 介绍
  • 预防性疫苗
  • 治疗性疫苗

第七章 癌症疫苗市场（依技术）

  • 介绍
  • 细胞疫苗
  • 重组疫苗
  • 其他的

第八章 癌症疫苗市场（依给药途径）

  • 介绍
  • 肌肉内给药
  • 其他的

第九章 癌症疫苗市场（按适应症）

  • 介绍
  • 子宫颈癌及相关癌症
  • 其他的

第10章癌症疫苗市场（依最终用户）

  • 介绍
  • 医院
  • 专科诊所和中心

第十一章 癌症疫苗市场（按地区）

  • 介绍
  • 亚太地区
    • 亚太宏观经济展望
    • 中国
    • 日本
    • 印度
    • 韩国
    • 其他的
  • 北美洲
    • 北美宏观经济前景
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲宏观经济展望
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 拉丁美洲
    • 拉丁美洲宏观经济展望
    • 巴西
    • 墨西哥
    • 其他的
  • 中东
    • 中东宏观经济展望
    • 海湾合作委员会国家
    • 其他的
  • 非洲
    • 增加对癌症疫苗免疫计划的投资以支持市场成长
    • 非洲宏观经济展望

第十二章竞争格局

  • 概述
  • 主要参与企业的策略/优势，2023 年
  • 2019-2023年收益分析
  • 2023 年和 2032 年市场排名
  • 企业评估矩阵：主要参与企业，2023
  • 企业评估矩阵：Start-Ups/小型企业，2023 年
  • 公司评价及财务指标
  • 品牌/产品比较
  • 竞争场景

第十三章 公司简介

  • 主要参与企业
    • MERCK & CO., INC.
    • GSK PLC.
    • DENDREON PHARMACEUTICALS LLC.（SANPOWER GROUP）
    • JW CREAGENE（JW SHINYAK）
    • SERUM INSTITUTE OF INDIA PVT. LTD.
    • VERITY PHARMACEUTICALS, INC.
    • WANTAI BIOPHARM
    • SHANGHAI ZERUN BIOTECH CO., LTD.（WALVAX BIOTECHNOLOGY CO., LTD.）
    • VACCINOGEN
  • 其他公司（产品正在进行临床试验的公司）
    • BIONTECH
    • GRITSTONE BIO
    • OSE-IMMUNO
    • OBI PHARMA
    • SHANGHAI BOVAX BIOTECHNOLOGY CO., LTD.
    • MODERNA INC.
    • BEIJING SINOCELL BIOTECHNOLOGY GROUP CO., LTD.
    • GREENWICH LIFESCIENCES, INC.
    • ASTON SCI. INC.
    • TRANSGENE
    • SELLAS LIFE SCIENCES GROUP INC.

第十四章附录

Product Code: PH 9230

The global cancer vaccines market is projected to surpass USD 20.47 billion in 2032 from USD 10.61 billion in 2024, with a significant CAGR of 8.6%. The market is witnessing robust growth, fueled by rising cancer prevalence and advancements in immunotherapy technologies like mRNA platforms. Preventive vaccines such as Gardasil (HPV) and therapeutic candidates like neoantigen vaccines are driving innovation in the market. Strong R&D investments, especially in North America and Europe, combined with increasing demand for personalized therapies, are further accelerating adoption.

Scope of the Report
Years Considered for the Study2022-2032
Base Year2023
Forecast Period2024-2032
Units ConsideredValue (USD)
SegmentsBy Type, Technology, Route of Administration, Indication and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The preventive cancer vaccines segment accounted for the highest share in 2023."

On the basis of type, the cancer vaccines market is further segmented into preventive and therapeutic vaccines (Neoantigen cancer vaccines and other cancer vaccines). The preventive cancer vaccines segment is anticipated to lead the cancer vaccines market, driven by increasing awareness of disease prevention, government immunization programs, and technological advancements in vaccine development. Emerging technologies, such as mRNA platforms, are further likely to enhance vaccine efficacy and accessibility is likely to boost the segmental growth.

"By route of administration, intramuscular segment accounted for the largest share in the cancer vaccines market."

The route of administration segment of the cancer vaccines market is segmented into intravenous, intramuscular, and other route of administration. Intramuscular (IM) route of administration is expected to lead the cancer vaccines market owing to the established practice, high efficacy of the administration of the vaccine, and creation of an effective immune response. IM administration guarantees a high efficiency of vaccine absorption and compatibility with any kind of formulation, therefore it is the most appropriate for preventive and treatment cancer vaccines. Its ease of use in clinical and outpatient settings, along with minimal training requirements for healthcare providers, enhances accessibility and scalability for mass immunization programs. All of these parameters therefore position the IM route as the dominant and feasible option in the cancer vaccine field.

"North America: the largest share of the cancer vaccines market"

By region, the market is segment into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America dominated the cancer vaccines market in 2023 and is estimated to continue dominance during the forecast period. Advanced healthcare infrastructure, high levels of investment in biotechnology, and strong presence of leading pharmaceutical companies driving innovation in the field. are some of the prominent factors accelerating market growth.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the cancer vaccines market.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 65% and Demand Side 35%
  • By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

Merck & Co., Inc. (US), GSK plc (UK), Dendreon Pharmaceuticals LLC (US), JW CreaGene (Korea), Serum Institute of India Pvt. Ltd. (India), Verity Pharmaceuticals, Inc. (Canada), Wantai BioPharm (China), Vaccinogen (US) and Shanghai Zerun Biotechnology Co., Ltd. (China) among others are some of the major players operating in the cancer vaccines market.

Research Coverage:

This research report categorizes the cancer vacciness market type (preventive and therapeutic [neoantigen cancer vaccines & other cancer vaccines]), technology (cell-based vaccines, recombinant, others), route of administration (intramuscular, intravenous, other routes of administration), indication (cervical cancer, prostrate cancer, other indications), end user (hospitals, others) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cancer vacciness market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the cancer vaccines market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the cancer vaccines and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increasing Awareness and Preventive Healthcare Measures, Rising Cancer Incidence Globally, Increased investments into R&D of Neoantigen cancer vaccines and Technological Advancements in Immunotherapy), restraints (Lengthy Clinical Trial Processes and Vaccine Hesitancy & Limited Adoption and High Development and Manufacturing Costs), opportunities (Collaborations & Strategic Partnerships and Incorporation of Artificial Intelligence (AI) & Big Data) and Challenges (Personalized Medicine & Heterogeneity of Cancer Types and Competition from Alternative Therapies) influencing the growth of the market.
  • Product Development/Innovation: Detailed insights on upcoming technologies in cancer vaccines manufacturing, research and development activities, and new product launches in the cancer vaccines market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cancer vaccines market
  • Competitive Assessment: Merck & Co., Inc. (US), GSK plc (UK), Dendreon Pharmaceuticals LLC (US), JW CreaGene (Korea), Serum Institute of India Pvt. Ltd. (India), Verity Pharmaceuticals, Inc. (Canada), Wantai BioPharm (China), Vaccinogen (US) and Shanghai Zerun Biotechnology Co., Ltd. (China) among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 MARKET ESTIMATION
    • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
    • 2.2.3 TOP-DOWN APPROACH
  • 2.3 MARKET GROWTH RATE PROJECTION
  • 2.4 DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 CANCER VACCINES MARKET OVERVIEW
  • 4.2 NORTH AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY AND COUNTRY (2023)
  • 4.3 CANCER VACCINES MARKET SHARE, BY TYPE, 2024 VS. 2032
  • 4.4 CANCER VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increased investments in neoantigen cancer vaccine R&D
      • 5.2.1.2 Technological advancements in immunotherapy
      • 5.2.1.3 Increasing awareness and preventive healthcare measures
      • 5.2.1.4 Rising cancer incidence globally
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High development and manufacturing costs
      • 5.2.2.2 Lengthy clinical trial processes & vaccine hesitancy and limited adoption
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Collaborations and strategic partnerships
      • 5.2.3.2 Incorporation of AI and big data
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Personalized medicine and heterogeneity of cancer types
      • 5.2.4.2 Competition from alternative therapies
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
    • 5.5.1 RAW MATERIAL PROVIDERS
    • 5.5.2 PRODUCT PROVIDERS
    • 5.5.3 END USERS
    • 5.5.4 REGULATORY LANDSCAPE
  • 5.6 TECHNOLOGY ANALYSIS
    • 5.6.1 KEY TECHNOLOGIES
      • 5.6.1.1 mRNA-based vaccines
      • 5.6.1.2 Dendritic cell vaccines
      • 5.6.1.3 Recombinant vector-based vaccines
    • 5.6.2 COMPLEMENTARY TECHNOLOGIES
      • 5.6.2.1 Artificial Intelligence (AI) and Machine Learning (ML)
      • 5.6.2.2 Adjuvants for immuno-stimulation
    • 5.6.3 ADJACENT TECHNOLOGIES
      • 5.6.3.1 CAR T-cell therapy
      • 5.6.3.2 CRISPR-based gene editing
  • 5.7 PATENT ANALYSIS
    • 5.7.1 METHODOLOGY
    • 5.7.2 NUMBER OF PATENTS FILED
    • 5.7.3 INNOVATIONS AND PATENT APPLICATIONS
  • 5.8 PRICING ANALYSIS
    • 5.8.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, 2021-2023
    • 5.8.2 AVERAGE SELLING PRICE, BY REGION, 2023
  • 5.9 KEY CONFERENCES & EVENTS, 2024-2O25
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.2 REGULATORY FRAMEWORK
      • 5.10.2.1 North America
      • 5.10.2.2 Europe
      • 5.10.2.3 Asia Pacific
  • 5.11 INVESTMENT & FUNDING SCENARIO
  • 5.12 PORTER'S FIVE FORCES ANALYSIS
    • 5.12.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.12.2 BARGAINING POWER OF SUPPLIERS
    • 5.12.3 BARGAINING POWER OF BUYERS
    • 5.12.4 THREAT OF SUBSTITUTES
    • 5.12.5 THREAT OF NEW ENTRANTS
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.13.1 KEY STAKEHOLDERS
    • 5.13.2 KEY BUYING CRITERIA
  • 5.14 TRADE ANALYSIS
    • 5.14.1 IMPORT DATA FOR HS CODE 300241
    • 5.14.2 EXPORT DATA FOR HS CODE 300241
  • 5.15 IMPACT OF AI/GEN AI ON CANCER VACCINES MARKET
  • 5.16 PIPELINE ANALYSIS

6 CANCER VACCINES MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 PREVENTIVE VACCINES
    • 6.2.1 NATIONAL IMMUNIZATION PROGRAMS & BIOTECHNOLOGY INNOVATIONS TO DRIVE MARKET GROWTH
  • 6.3 THERAPEUTIC VACCINES
    • 6.3.1 NEOANTIGEN CANCER VACCINES
      • 6.3.1.1 Personalized nature of neoantigen cancer vaccines to propel market growth
    • 6.3.2 OTHER THERAPEUTIC VACCINES

7 CANCER VACCINES MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 CELL-BASED VACCINES
    • 7.2.1 ADVANCEMENTS IN MANUFACTURING PROCESSES TO DRIVE MARKET GROWTH
  • 7.3 RECOMBINANT VACCINES
    • 7.3.1 GLOBAL VACCINATION INITIATIVES TO PROPEL MARKET
  • 7.4 OTHER VACCINE TECHNOLOGIES

8 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION

  • 8.1 INTRODUCTION
  • 8.2 INTRAMUSCULAR ROUTE
    • 8.2.1 TECHNOLOGICAL ADVANCEMENTS IN VACCINE DELIVERY TO SUPPORT MARKET GROWTH
  • 8.3 OTHER ROUTES OF ADMINISTRATION

9 CANCER VACCINES MARKET, BY INDICATION

  • 9.1 INTRODUCTION
  • 9.2 CERVICAL & RELATED CANCERS
    • 9.2.1 RISING CERVICAL CANCER PREVALENCE TO SUPPORT MARKET GROWTH
  • 9.3 OTHER INDICATIONS

10 CANCER VACCINES MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS
    • 10.2.1 RISING CANCER PREVALENCE TO SUPPORT MARKET GROWTH
  • 10.3 SPECIALTY CLINICS & CENTERS
    • 10.3.1 INCREASING AWARENESS AND ACCESS TO PROPEL MARKET

11 CANCER VACCINES MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 ASIA PACIFIC
    • 11.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.2.2 CHINA
      • 11.2.2.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China
    • 11.2.3 JAPAN
      • 11.2.3.1 Government initiatives for vaccines to boost market
    • 11.2.4 INDIA
      • 11.2.4.1 Growth of biotechnology sector and development of new vaccines to drive market
    • 11.2.5 SOUTH KOREA
      • 11.2.5.1 Commitment to cancer immunotherapy to expand cancer vaccine sector
    • 11.2.6 REST OF ASIA PACIFIC
  • 11.3 NORTH AMERICA
    • 11.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.3.2 US
      • 11.3.2.1 US to dominate North American market during forecast period
    • 11.3.3 CANADA
      • 11.3.3.1 Increasing government funding for vaccine research to drive market growth in Canada
  • 11.4 EUROPE
    • 11.4.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.4.2 GERMANY
      • 11.4.2.1 Increasing investments by key players and growing funding from government organizations to drive market
    • 11.4.3 UK
      • 11.4.3.1 Rising investments in vaccine development to boost market growth
    • 11.4.4 FRANCE
      • 11.4.4.1 Support for biotechnology and research to drive market growth
    • 11.4.5 ITALY
      • 11.4.5.1 Government initiatives for vaccine development to boost market growth
    • 11.4.6 SPAIN
      • 11.4.6.1 Increasing investments in vaccine development by government and private organizations to support market growth
    • 11.4.7 REST OF EUROPE
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Proactive healthcare policies to support market growth
    • 11.5.3 MEXICO
      • 11.5.3.1 Government commitment to immunization programs to fuel growth
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 11.6.2 GCC COUNTRIES
    • 11.6.3 REST OF MIDDLE EAST
  • 11.7 AFRICA
    • 11.7.1 INCREASING INVESTMENTS IN CANCER VACCINE IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH
    • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER VACCINES MARKET
  • 12.3 REVENUE ANALYSIS, 2019-2023
  • 12.4 MARKET RANKING, 2023 AND 2032
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Region footprint
      • 12.5.5.3 Type footprint
      • 12.5.5.4 Technology footprint
      • 12.5.5.5 Route of administration footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    • 12.7.1 FINANCIAL METRICS
    • 12.7.2 COMPANY VALUATION
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES & APPROVALS
    • 12.9.2 DEALS
    • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 MERCK & CO., INC.
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Deals
        • 13.1.1.3.2 Expansions
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Key strengths
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses & competitive threats
    • 13.1.2 GSK PLC.
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Product approvals
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Key strengths
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses & competitive threats
    • 13.1.3 DENDREON PHARMACEUTICALS LLC. (SANPOWER GROUP)
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 MnM view
        • 13.1.3.3.1 Key strengths
        • 13.1.3.3.2 Strategic choices
        • 13.1.3.3.3 Weaknesses & competitive threats
    • 13.1.4 JW CREAGENE (JW SHINYAK)
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
    • 13.1.5 SERUM INSTITUTE OF INDIA PVT. LTD.
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Product launches
        • 13.1.5.3.2 Deals
    • 13.1.6 VERITY PHARMACEUTICALS, INC.
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Product approvals
    • 13.1.7 WANTAI BIOPHARM
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
    • 13.1.8 SHANGHAI ZERUN BIOTECH CO., LTD. (WALVAX BIOTECHNOLOGY CO., LTD.)
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Product approvals
    • 13.1.9 VACCINOGEN
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
  • 13.2 OTHER PLAYERS (COMPANIES WITH PRODUCTS UNDER CLINICAL STUDIES)
    • 13.2.1 BIONTECH
      • 13.2.1.1 BioNTech: Products under clinical studies
    • 13.2.2 GRITSTONE BIO
      • 13.2.2.1 Gritstone Bio: Products under clinical studies
    • 13.2.3 OSE-IMMUNO
      • 13.2.3.1 OSE-Immuno: Products under clinical studies
    • 13.2.4 OBI PHARMA
      • 13.2.4.1 OBI Pharma: Products under clinical studies
    • 13.2.5 SHANGHAI BOVAX BIOTECHNOLOGY CO., LTD.
      • 13.2.5.1 Shanghai Bovax Biotechnology: Products under clinical studies
    • 13.2.6 MODERNA INC.
      • 13.2.6.1 Moderna: Products under clinical studies
    • 13.2.7 BEIJING SINOCELL BIOTECHNOLOGY GROUP CO., LTD.
      • 13.2.7.1 Beijing Sinocell Biotechnology Group: Products under clinical studies
    • 13.2.8 GREENWICH LIFESCIENCES, INC.
      • 13.2.8.1 Greenwich LifeSciences: Products under clinical studies
    • 13.2.9 ASTON SCI. INC.
      • 13.2.9.1 Aston Sci.: Products under clinical studies
    • 13.2.10 TRANSGENE
      • 13.2.10.1 Transgene: Products under clinical studies
    • 13.2.11 SELLAS LIFE SCIENCES GROUP INC.
      • 13.2.11.1 Sellas Life Sciences Group: Products under clinical studies

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 2 CANCER VACCINES MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 3 KEY RAW MATERIAL PROVIDERS IN CANCER VACCINES MARKET
  • TABLE 4 KEY PRODUCT PROVIDERS IN CANCER VACCINES MARKET
  • TABLE 5 KEY END USERS IN CANCER VACCINES MARKET
  • TABLE 6 KEY REGULATORY BODIES IN CANCER VACCINES MARKET
  • TABLE 7 NUMBER OF PATENTS FILED IN CANCER VACCINES MARKET, BY DOCUMENT TYPE, 2014-2024
  • TABLE 8 LIST OF PATENTS IN CANCER VACCINES MARKET, 2023-2024
  • TABLE 9 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY TYPE, 2021-2023
  • TABLE 10 AVERAGE SELLING PRICE OF CANCER VACCINES, BY REGION, 2023
  • TABLE 11 KEY CONFERENCES & EVENTS, JUNE 2024-DECEMBER 2025
  • TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 CANCER VACCINES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
  • TABLE 19 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • TABLE 20 IMPORT VALUE FOR HS CODE 300241, 2019-2023 (USD THOUSAND)
  • TABLE 21 IMPORT VOLUME FOR HS CODE 300241, 2019-2023 (TONS)
  • TABLE 22 EXPORT VALUE FOR HS CODE 300241, 2019-2023 (USD THOUSAND)
  • TABLE 23 EXPORT VOLUME FOR HS CODE 300241, 2019-2023 (TONS)
  • TABLE 24 CANCER VACCINES MARKET: PRODUCTS IN PIPELINE AND LAUNCH DATES
  • TABLE 25 CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 26 PREVENTIVE CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 27 NORTH AMERICA: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 28 EUROPE: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 30 LATIN AMERICA: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 31 MIDDLE EAST: PREVENTIVE CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 32 THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 33 THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 34 NORTH AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 35 EUROPE: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 37 LATIN AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 38 MIDDLE EAST: THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 39 NEOANTIGEN CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 40 NORTH AMERICA: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 41 EUROPE: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 42 ASIA PACIFIC: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 43 LATIN AMERICA: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 44 MIDDLE EAST: NEOANTIGEN CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 45 OTHER THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 46 NORTH AMERICA: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 47 EUROPE: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 48 ASIA PACIFIC: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 49 LATIN AMERICA: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 50 MIDDLE EAST: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 51 CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 52 CELL-BASED CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 53 NORTH AMERICA: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 54 EUROPE: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 56 LATIN AMERICA: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 57 MIDDLE EAST: CELL-BASED CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 58 RECOMBINANT CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 59 NORTH AMERICA: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 60 EUROPE: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 62 LATIN AMERICA: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 63 MIDDLE EAST: RECOMBINANT CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 64 OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 65 NORTH AMERICA: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 66 EUROPE: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 68 LATIN AMERICA: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 69 MIDDLE EAST: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 70 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 71 CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 72 NORTH AMERICA: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 73 EUROPE: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 74 ASIA PACIFIC: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 75 LATIN AMERICA: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 76 MIDDLE EAST: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 77 CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 78 NORTH AMERICA: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 79 EUROPE: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 81 LATIN AMERICA: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 82 MIDDLE EAST: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 83 CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 84 CERVICAL & RELATED CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 85 NORTH AMERICA: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 86 EUROPE: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032(USD MILLION)
  • TABLE 87 ASIA PACIFIC: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 88 LATIN AMERICA: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 89 MIDDLE EAST: CERVICAL & RELATED CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 90 CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 91 NORTH AMERICA: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 92 EUROPE: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2032(USD MILLION)
  • TABLE 93 ASIA PACIFIC: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 94 LATIN AMERICA: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 95 MIDDLE EAST: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 96 CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 97 CANCER VACCINES MARKET FOR HOSPITALS, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 98 NORTH AMERICA: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 99 EUROPE: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 100 ASIA PACIFIC: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 101 LATIN AMERICA: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 102 MIDDLE EAST: CANCER VACCINES MARKET FOR HOSPITALS, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 103 CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 104 NORTH AMERICA: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 105 EUROPE: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 106 ASIA PACIFIC: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 107 LATIN AMERICA: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 108 MIDDLE EAST: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 109 CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 111 ASIA PACIFIC: CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 118 CHINA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 119 CHINA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 120 CHINA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 121 CHINA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 122 CHINA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 123 CHINA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 124 JAPAN: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 125 JAPAN: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 126 JAPAN: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 127 JAPAN: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 128 JAPAN: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 129 JAPAN: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 130 INDIA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 131 INDIA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 132 INDIA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 133 INDIA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 134 INDIA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 135 INDIA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 136 SOUTH KOREA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 137 SOUTH KOREA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 138 SOUTH KOREA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 139 SOUTH KOREA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 140 SOUTH KOREA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 141 SOUTH KOREA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 142 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 143 REST OF ASIA PACIFIC: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 144 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 145 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 146 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 147 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 148 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 149 NORTH AMERICA: CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 150 NORTH AMERICA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 151 NORTH AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 152 NORTH AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 153 NORTH AMERICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 154 NORTH AMERICA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 155 NORTH AMERICA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 156 US: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 157 US: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 158 US: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 159 US: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 160 US: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 161 US: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 162 CANADA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 163 CANADA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 164 CANADA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 165 CANADA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 166 CANADA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 167 CANADA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 168 EUROPE: KEY MACROINDICATORS
  • TABLE 169 EUROPE: CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 170 EUROPE: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 171 EUROPE: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 172 EUROPE: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 173 EUROPE: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 174 EUROPE: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 175 EUROPE: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 176 GERMANY: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 177 GERMANY: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 178 GERMANY: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 179 GERMANY: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 180 GERMANY: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 181 GERMANY: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 182 UK: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 183 UK: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 184 UK: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 185 UK: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 186 UK: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 187 UK: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 188 FRANCE: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 189 FRANCE: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 190 FRANCE: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 191 FRANCE: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 192 FRANCE: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 193 FRANCE: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 194 ITALY: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 195 ITALY: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 196 ITALY: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 197 ITALY: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 198 ITALY: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 199 ITALY: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 200 SPAIN: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 201 SPAIN: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 202 SPAIN: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 203 SPAIN: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 204 SPAIN: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 205 SPAIN: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 206 REST OF EUROPE: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 207 REST OF EUROPE: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 208 REST OF EUROPE: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 209 REST OF EUROPE: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 210 REST OF EUROPE: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 211 REST OF EUROPE: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 212 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 213 LATIN AMERICA: CANCER VACCINES MARKET, BY COUNTRY, 2022-2032 (USD MILLION)
  • TABLE 214 LATIN AMERICA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 215 LATIN AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 216 LATIN AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 217 LATIN AMERICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 218 LATIN AMERICA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 219 LATIN AMERICA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 220 BRAZIL: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 221 BRAZIL: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 222 BRAZIL: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 223 BRAZIL: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 224 BRAZIL: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 225 BRAZIL: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 226 MEXICO: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 227 MEXICO: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 228 MEXICO: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 229 MEXICO: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 230 MEXICO: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 231 MEXICO: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 232 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 233 REST OF LATIN AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 234 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 235 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 236 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 237 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 238 MIDDLE EAST: KEY MACROINDICATORS
  • TABLE 239 MIDDLE EAST: CANCER VACCINES MARKET, BY REGION, 2022-2032 (USD MILLION)
  • TABLE 240 MIDDLE EAST: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 241 MIDDLE EAST: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 242 MIDDLE EAST: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 243 MIDDLE EAST: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 244 MIDDLE EAST: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 245 MIDDLE EAST: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 246 GCC COUNTRIES: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 247 GCC COUNTRIES: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 248 GCC COUNTRIES: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 249 GCC COUNTRIES: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 250 GCC COUNTRIES: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 251 GCC COUNTRIES: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 252 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 253 REST OF MIDDLE EAST: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 254 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 255 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 256 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 257 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 258 AFRICA: KEY MACROINDICATORS
  • TABLE 259 AFRICA: CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 260 AFRICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022-2032 (USD MILLION)
  • TABLE 261 AFRICA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022-2032 (USD MILLION)
  • TABLE 262 AFRICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 (USD MILLION)
  • TABLE 263 AFRICA: CANCER VACCINES MARKET, BY INDICATION, 2022-2032 (USD MILLION)
  • TABLE 264 AFRICA: CANCER VACCINES MARKET, BY END USER, 2022-2032 (USD MILLION)
  • TABLE 265 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2021-2024
  • TABLE 266 CANCER VACCINES MARKET SHARE RANKING (2023)
  • TABLE 267 CANCER VACCINES MARKET SHARE RANKING (2032)
  • TABLE 268 CANCER VACCINES MARKET: REGION FOOTPRINT
  • TABLE 269 CANCER VACCINES MARKET: TYPE FOOTPRINT
  • TABLE 270 CANCER VACCINES MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 271 CANCER VACCINES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
  • TABLE 272 CANCER VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 273 CANCER VACCINES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 274 CANCER VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 275 CANCER VACCINES MARKET: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 276 CANCER VACCINES MARKET: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 277 MERCK: COMPANY OVERVIEW
  • TABLE 278 MERCK: PRODUCTS OFFERED
  • TABLE 279 MERCK: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 280 MERCK: EXPANSIONS, JANUARY 2021-NOVEMBER 2024
  • TABLE 281 GSK: COMPANY OVERVIEW
  • TABLE 282 GSK: PRODUCTS OFFERED
  • TABLE 283 GSK: PRODUCT APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 284 DENDREON PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 285 DENDREON PHARMACEUTICALS: PRODUCTS OFFERED
  • TABLE 286 JW CREAGENE: COMPANY OVERVIEW
  • TABLE 287 JW CREAGENE: PRODUCTS OFFERED
  • TABLE 288 SERUM INSTITUTE OF INDIA: COMPANY OVERVIEW
  • TABLE 289 SERUM INSTITUTE OF INDIA: PRODUCTS OFFERED
  • TABLE 290 SERUM INSTITUTE OF INDIA: PRODUCT LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 291 SERUM INSTITUTE OF INDIA: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 292 VERITY PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 293 VERITY PHARMACEUTICALS: PRODUCTS OFFERED
  • TABLE 294 VERITY PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 295 WANTAI BIOPHARM: COMPANY OVERVIEW
  • TABLE 296 WANTAI BIOPHARM: PRODUCTS OFFERED
  • TABLE 297 SHANGHAI ZERUN BIOTECHNOLOGY: COMPANY OVERVIEW
  • TABLE 298 SHANGHAI ZERUN BIOTECHNOLOGY: PRODUCTS OFFERED
  • TABLE 299 SHANGHAI ZERUN BIOTECHNOLOGY: PRODUCT APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 300 VACCINOGEN: COMPANY OVERVIEW
  • TABLE 301 VACCINOGEN: PRODUCTS OFFERED

List of Figures

  • FIGURE 1 CANCER VACCINES MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARIES: CANCER VACCINES MARKET
  • FIGURE 4 CANCER VACCINES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
  • FIGURE 5 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (PRODUCTS), 2023
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF MERCK & CO., INC.: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 9 CANCER VACCINES MARKET: CAGR PROJECTIONS
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 CANCER VACCINES MARKET, BY TYPE, 2024 VS. 2032 (USD MILLION)
  • FIGURE 12 CANCER VACCINES MARKET, BY TECHNOLOGY, 2024 VS. 2032 (USD MILLION)
  • FIGURE 13 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2032 (USD MILLION)
  • FIGURE 14 CANCER VACCINES MARKET, BY INDICATION, 2024 VS. 2032 (USD MILLION)
  • FIGURE 15 CANCER VACCINES MARKET, BY END USER, 2024 VS. 2032 (USD MILLION)
  • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CANCER VACCINES MARKET (2024-2032)
  • FIGURE 17 ADVANCEMENTS IN CANCER VACCINES AND RISING DEMAND FOR NEOANTIGEN CANCER VACCINES TO DRIVE MARKET
  • FIGURE 18 RECOMBINANT VACCINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 19 PREVENTIVE VACCINES TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 20 US TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 21 CANCER VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 TRENDS/DISRUPTIONS INFLUENCING CUSTOMERS' BUSINESS
  • FIGURE 23 CANCER VACCINES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 24 CANCER VACCINES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 25 CANCER VACCINES MARKET: PATENT ANALYSIS
  • FIGURE 26 CANCER VACCINES MARKET: FUNDING SCENARIO
  • FIGURE 27 CANCER VACCINES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
  • FIGURE 29 KEY BUYING CRITERIA FOR TOP END USERS
  • FIGURE 30 CANCER VACCINES MARKET: IMPACT OF AI
  • FIGURE 31 ASIA PACIFIC: CANCER VACCINES MARKET SNAPSHOT
  • FIGURE 32 NORTH AMERICA: CANCER VACCINES MARKET SNAPSHOT
  • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN CANCER VACCINES MARKET, 2019-2023
  • FIGURE 34 CANCER VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 35 CANCER VACCINES MARKET: COMPANY FOOTPRINT
  • FIGURE 36 CANCER VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 37 EV/EBITDA OF KEY VENDORS
  • FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 39 CANCER VACCINES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 40 MERCK: COMPANY SNAPSHOT (2023)
  • FIGURE 41 GSK: COMPANY SNAPSHOT (2023)